NASDAQ:RGC Regencell Bioscience (RGC) Stock Price, News & Analysis $6.19 +0.21 (+3.51%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About Regencell Bioscience Stock (NASDAQ:RGC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Regencell Bioscience alerts:Sign Up Key Stats Today's Range$5.91▼$6.2150-Day Range$4.78▼$6.8952-Week Range$4.51▼$69.00Volume54,832 shsAverage Volume289,654 shsMarket Capitalization$3.06 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Regencell Bioscience Holdings Limited (NASDAQ:RGC) is a clinical-stage biotechnology company focused on developing traditional Chinese medicine (TCM)-based treatments for neurological and neurocognitive disorders. The company’s research is centered on formulations intended to address conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), as well as other disorders affecting brain function. Regencell’s product candidates include RGC-M001, a proprietary TCM formulation being developed for ADHD and ASD, and RGC-M002, a formulation being investigated for dementia-related conditions. The company’s approach combines traditional Chinese medicine principles with research and clinical development intended to evaluate the safety and potential effectiveness of its treatments. Regencell is based in Hong Kong and conducts its development activities through research and clinical initiatives in the region. The company was founded by Yat-Gai Au, who serves as its chief executive officer. Regencell completed its initial public offering on the Nasdaq Capital Market in 2021 and remains focused on advancing its TCM-based product candidates through development.AI Generated. May Contain Errors. Read More Regencell Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks3rd Percentile Overall ScoreRGC MarketRank™: Regencell Bioscience scored higher than 3% of companies evaluated by MarketBeat, and ranked 893rd out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingRegencell Bioscience has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageRegencell Bioscience has only been the subject of 1 research reports in the past 90 days.Read more about Regencell Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioRegencell Bioscience has a P/B Ratio of 605.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.20% of the float of Regencell Bioscience has been sold short.Short Interest Ratio / Days to CoverRegencell Bioscience has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Regencell Bioscience has recently decreased by 3.90%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldRegencell Bioscience does not currently pay a dividend.Dividend GrowthRegencell Bioscience does not have a long track record of dividend growth.Read more about Regencell Bioscience's dividend. News and Social Media0.7 / 5News SentimentN/A News SentimentRegencell Bioscience has a news sentiment score of -0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Regencell Bioscience this week, compared to 4 articles on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Regencell Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders2.00% of the stock of Regencell Bioscience is held by insiders.Percentage Held by Institutions0.13% of the stock of Regencell Bioscience is held by institutions.Read more about Regencell Bioscience's insider trading history. Receive RGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regencell Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RGC Stock News HeadlinesRegencell Bioscience: I Got It Wrong (Rating Downgrade)September 23 at 9:17 AM | seekingalpha.comRGC Resources: More Likely To Appeal More To Income-Focused InvestorsAugust 18, 2026 | seekingalpha.comMy next big call (under $1)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called to our community before the big move happened… And right now, I'm making my next big call. It's a coin trading under $1.00… one most investors have never even heard of. But the world's largest bank is already building on it. It has a burn mechanism wired directly to institutional usage… meaning the more the big money uses it, the more rare it becomes. And its biggest supply cut in history happened earlier this year…September 24 at 1:00 AM | Crypto 101 Media (Ad)Regencell Bioscience Posts Higher Losses in First-Half 2026 Results Filed on Form 6-KJuly 3, 2026 | theglobeandmail.comRegencell Bioscience surges on apparent short squeezeJuly 1, 2026 | msn.comRegencell Bioscience Holdings Limited (NASDAQ: RGC) Investors Have Until June 23, 2026 to Seek a Leadership Role in the Securities Class Action Lawsuit Contact Kaplan Fox ...June 30, 2026 | theglobeandmail.comPomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limitedand Certain Officers – RGCJune 23, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor HarmJune 23, 2026 | prnewswire.comSee More Headlines RGC Stock Analysis - Frequently Asked Questions How have RGC shares performed this year? Regencell Bioscience's stock was trading at $21.00 on January 1st, 2026. Since then, RGC stock has decreased by 71.2% and is now trading at $6.0550. When did Regencell Bioscience's stock split? Regencell Bioscience's stock split before market open on Monday, June 16th 2025.The 38-1 split was announced on Monday, June 2nd 2025. The newly issued shares were payable to shareholders after the closing bell on Sunday, June 15th 2025. An investor that had 100 shares of stock prior to the split would have 3,800 shares after the split. When did Regencell Bioscience IPO? Regencell Bioscience (RGC) raised $22 million in an IPO on Wednesday, July 14th 2021. The company issued 2,300,000 shares at $8.50-$10.50 per share. Who are Regencell Bioscience's major shareholders? Top institutional investors of Regencell Bioscience include Squarepoint Ops LLC. How do I buy shares of Regencell Bioscience? Shares of RGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/24/2026Fiscal Year End6/30/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RGC Previous SymbolNASDAQ:RGC CIK1829667 Webregencellbioscience.com Phone852 2155 0823Fax852-2155-0853Employees10Year Founded2014Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.41 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book604.50Miscellaneous Outstanding Shares494,489,000Free Float484,599,000Market Cap$2.99 billion OptionableN/A Beta1.45 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:RGC) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredArizona Gold Explorer Nears First-Ever Resource EstimateA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...Wall Street Logic | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...Behind the Markets | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regencell Bioscience Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Regencell Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
